Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected
Comparing 2 of 2 drugs
× ×
Change selection
2 drug columns · use arrows or scrollbar
Field N-ACETYL CYSTEINE (NAC)
Antidotes · Antidotes · Level 3
Intralipid 20%
Antidotes · Antidotes · Level 3
Mechanism of action

- Metabolized to cysteine → Regeneration of sulphydril groups and glutathione
- acting as an alternate substrate for conjugation
- reduces disulfide bonds in mucoproteins

- unclear
- may involve establishment of concentration gradient away from primary site of action of LA

Physiological effects

- Reduces hepatotoxicity
- mucolytic

- energy substrate (essential fatty acids)
- managing lipophilic drug overdose by binding and facilitating clearance

Absorption

PO: BA low

IV only

Protein binding

66-97%
Albumin

None

Volume of distribution

0.5 L/kg

Wide - distributed to fat and tissues

Metabolism

Liver
Deacetylated to cysteine -> normal metabolism (Rapid)

Liver
Broken down to Fatty acids and glycerol

Excretion

Unchanged: 40% urine, 3% feces

Liver and kidneys

Half-life

5.5 hrs

not well defined

Adverse Effects Toxicity

usually in 1st hr:
- rash around infusion site
- angiooedema
- bronchospasm
- hypo/hyper tension

Mx: stop, give antihistamine, then restart at slowest infusion rate

- Fat embolism
- Hyperlipidemia, pancreatitis
- Hepatic dysfunction
- Allergic reactions

Chemical Pharmaceutics

Synthetic derivative of cysteine

fat emulsion

Class Group

Antidote

Antidote


Antidotes · Antidotes

Antidotes

Indications Uses

- paracetamol overdose
- non-paracetamol induced fulminant hepatic failure
- prevention of contrast nephropathy
- mucolytic therapy

- TPN mixtures
- Local anaesthetic toxicity with or without circulatory arrest
- Prevention of essential fatty acid deficiency syndrome

Legacy Cicm Level

Level 3

Level 3

Main Action

antioxidant and glutathione inducer

- Energy substrate
- Reverse local anaesthetic cardiotoxicity

Onset Peak Duration

Duration: short

(For LA tox)
onset: minutes
peak: 15-30mins

Presentation

IV or oral formulation
200mg/mL
compatible with 5% dextrose

white, oil-water emulsion with 20% soybean oil, egg yolk phospholipids, glycerin, sodium hydroxide and water

Route And Dose

IV, PO, Neb (inhaled)

IV:
1st : 150mg/kg in 200ml dextrose over 15mins
2nd : 50mg/kg in 500ml over 4hrs
3rd : 100mg/kg in 1l over 16hrs

IV

For LA tox: 1.5ml/kg bolus over 1 minute →
Infusion 15 ml/kg/hr

If not stabilized, two subsequent boluses may be given 5 mins apark.
Then rate doubled to 30ml/kg/hr

Max cumulative dose 12ml/kg

Special Points —

serum amylase or lipase should be monitored for
2 days